SCHEMBL26732910

SCHEMBL26732910

CC(C)c1n[nH]c(=O)c2cc(C(F)(F)F)ccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ PDE2A O00408 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NOTUM Q6P988 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PRMT5 O14744 1/20 0.38
▸ WDR77 Q9BQA1 1/20 0.38
▸ AURKB Q96GD4 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ MAP2K4 P45985 2/20 0.37
▸ MAPKAPK3 Q16644 2/20 0.37
▸ MAPK6 Q16659 2/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ TRPA1 O75762 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29426515 1.00 PARP1 (0.42) PARP1POLBMAPTPDE2ASMN1; SMN2
SCHEMBL24076896 0.94 MAPT (0.44) PARP1POLBMAPTPDE2ASMN1; SMN2
SCHEMBL29426569 0.94 MAPT (0.44) PARP1POLBMAPTPDE2ASMN1; SMN2
SCHEMBL24076281 0.83 POLB (0.40) POLBMAPTPDE2ASMN1; SMN2PRMT5
SCHEMBL24076279 0.81 POLB (0.42) POLBMAPTSMN1; SMN2NOTUMPRMT5
SCHEMBL30451535 0.81 MAPT (0.45) PARP1MAPTPDE2ASMN1; SMN2HSD17B10
SCHEMBL26732593 0.81 MAPT (0.45) PARP1MAPTPDE2ASMN1; SMN2HSD17B10
SCHEMBL29875057 0.80 POLB (0.44) PARP1POLBMAPTTSHR
SCHEMBL15723643 0.80 MAP2K4 (0.52) GSK3BKDM4EMAPK1MAP2K4MAPKAPK3
SCHEMBL16675888 0.80 TRPA1 (0.51) MAPTHSD17B10GSK3BMAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 PARP1 1511/4885POLB 3737/4885MAPT 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback